Related Experiment Video

Updated: Aug 7, 2026

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

Development of small-molecule cyclin D1-ablative agents

Jui-Wen Huang1, Chung-Wai Shiau, Jian Yang

  • 1Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, 336 Parks Hall, The Ohio State University, 500 West 12th Avenue, Columbus, Ohio 43210, USA.

Journal of Medicinal Chemistry
|July 21, 2006
PubMed

Insights

A novel compound, STG28, effectively reduces cyclin D1 levels in breast cancer cells. This targeted approach inhibits cancer cell proliferation and may offer new therapeutic strategies for cancer treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Discovery

Background:

  • Cyclin D1 is a key regulator of cell cycle progression.
  • Overexpression of cyclin D1 is implicated in tumorigenesis and drug resistance.
  • Previous studies identified troglitazone's ability to repress cyclin D1 via a PPARgamma-independent pathway.

Purpose of the Study:

  • To develop novel cyclin D1-ablative agents.
  • To investigate the therapeutic potential of STG28, a structural analog of troglitazone.
  • To evaluate STG28's mechanism of action and specificity in breast cancer cells.

Main Methods:

  • Synthesis and structural optimization of troglitazone analogs.
  • Assessment of cyclin D1 repression and proteasomal degradation.
  • Evaluation of cell proliferation inhibition in MCF-7 breast cancer cells.
  • Analysis of STG28's specificity on other cyclins and CDK-dependent kinases.

Main Results:

  • STG28, derived from Delta2TG, effectively ablates cyclin D1 at low micromolar concentrations.
  • STG28 induces proteasomal degradation of cyclin D1 with high specificity.
  • STG28 inhibits MCF-7 cell proliferation.
  • STG28 does not significantly alter the expression of other cyclins or CDKs.

Conclusions:

  • STG28 is a potent and specific cyclin D1-ablating agent.
  • The PPARgamma-independent mechanism of cyclin D1 repression is maintained in STG28.
  • STG28 demonstrates therapeutic relevance as a potential anti-cancer agent targeting cyclin D1.

More Related Videos

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
Positive Regulator Molecules01:45

Positive Regulator Molecules

To consistently produce healthy cells, the cell cycle—the process that generates daughter cells—must be precisely regulated.
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Anaphase Promoting Complex00:50

Anaphase Promoting Complex

The stepwise destruction of specific proteins is necessary for the progression and completion of the cell cycle. Such proteins are ubiquitinated by ubiquitin ligases and then subsequently destroyed by the proteasome. The SCF (Skp1/Cullin/F-box) and the anaphase-promoting complex (APC) are two important ubiquitin ligases involved in cell cycle progression. While SCF is active throughout the cell cycle, APC gets activated during metaphase to anaphase transition. Cdc20 or Cdh1 binds to APC and...